retatrutide phase 2 diabetes weight loss 2024 This data from 3 clinical trials for was announced yesterday at @amdiabetesassn #ADA2026 ✓ We are fortunate to be living in a time where there multiple medications which safely reduce New Phase 3 retatrutide data

While endocrinologists and internists still dominate prescribing, nondiabetes specialists have increased GLP1 prescribing by 900% since 2020, signaling a fundamental shift in perception and adoption as audiences expand beyond traditional prescribers

Transport and inhibition mechanism of the human SGLT2-MAP17 glucose transporter

A higher percentage of semaglutide users achieved greater weight loss

The new science of weight loss drugs The new GLP-1 drugs Older weight-loss drugs Side effects of GLP-1 drugs Common side effects Rare but serious side effects Things to consider Benefits for other health conditions Nutrition and lifestyle considerations Energy and nutrient intake Protein and muscle health Physical activity Fiber and gastrointestinal function Fluid intake Support for the long haul Resources Reviews No reviews have been left for this newsletter

The newlyapproved innovative drug will be suitable for obese or overweight patients withan initial BMI of 30kg/m2 or greater or between 27kg/m2 and 30kg/m2 with atleast one weight-related comorbiditis

Arie Blitz Next steps: Consult your physician or telehealth provider about GLP-1 eligibility